Search for: "D. S." Results 661 - 680 of 236,439
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Sep 2024, 5:52 pm by Kurt R. Karst
§ 314.53(d)(5) (“Patent information will be considered to be submitted to FDA for purposes of paragraph (d)(3) of this section as of the earlier of the date the information submitted on Form FDA 3542 is date-stamped by the Central Document Room, or officially received by FDA in an electronic format submission that complies with § 314.50(l)(5)”), which states that once patent information is received by FDA it is considered submitted and Orange Book-listed . . .… [read post]
2 Sep 2024, 4:19 pm by Stephen Bilkis
Div. 2015), the court had to decide whether the facility qualified as a “residential health care facility” under New York’s Public Health Law § 2801-d. [read post]
2 Sep 2024, 12:29 pm
Es importante señalar que estas cifras pueden estar infladas debido a definiciones y protocolos inconsistentes o a una débil comprensión de la agresión sexual. [read post]
2 Sep 2024, 12:26 pm by Evidence ProfBlogger
Similar to its federal counterpart, South Carolina Rule of Evidence 801(d)(2)(B) provides an exclusion to the rule against hearsay for The statement is offered against a party and is...a statement of which the party has manifested an adoption or belief... [read post]
2 Sep 2024, 9:15 am by Lucas Thrun
In the original ruling, which was covered in a separate article, the CAFC held that the Patent Trial and Appeal Board (PTAB) properly applied the estoppel provision of 37 CFR § 42.73(d)(3)(i) in invalidating SoftView’s amended claims submitted in inter partes reexaminations based on a prior inter partes review (IPR) decision. [read post]
2 Sep 2024, 9:15 am by Lucas Thrun
In the original ruling, which was covered in a separate article, the CAFC held that the Patent Trial and Appeal Board (PTAB) properly applied the estoppel provision of 37 CFR § 42.73(d)(3)(i) in invalidating SoftView’s amended claims submitted in inter partes reexaminations based on a prior inter partes review (IPR) decision. [read post]
2 Sep 2024, 7:16 am by Kevin LaCroix
What is ESG-Related D&O Risk Going to Look Like Going Forward? [read post]
2 Sep 2024, 6:30 am
In other words, if settlement of the M&A claim would result in the acquired company’s shareholders receiving more value for the sale of the company, then the settlement will not be covered by the D&O policy. [read post]
2 Sep 2024, 6:30 am
In other words, if settlement of the M&A claim would result in the acquired company’s shareholders receiving more value for the sale of the company, then the settlement will not be covered by the D&O policy. [read post]
1 Sep 2024, 11:29 pm by lennyesq
In his letter [PDF] to Judge William Alsup, Boucher says that passage “mischaracterize[s] my work in a manner that has led to reputational harm, including causing a major media outlet to refer to me incorrectly as a ‘fraudster.'” The letter – a request rather than a defamation lawsuit at this point – scolds the plaintiffs’ attorneys (cc’d) for the unwarranted use of his name to support their claims against Anthropic. [read post]
1 Sep 2024, 8:48 pm by Binnall Law Group
In the era of the Administrative State, it might seem that federal agencies have the power to create, expand, or amend any laws that they’d like. [read post]
1 Sep 2024, 5:46 am
 If only you'd had the sense and the restraint to delete most of the words. [read post]
1 Sep 2024, 4:02 am by SHG
Treat them with respect — just the way you’d like them to treat you. [read post]